EAACI Guidelines on Allergen Immunotherapy: Executive Statement

A. Muraro; G. Roberts; S. Halken; A. Agache; L. Angier; M. Fernandez-Rivas; R. Gerth van Wijk; M. Jutel; S. Lau; G. Pajno; O. Pfaar; D. Ryan; G. J. Sturm; R. van Ree; E.-M. Varga; C. Bachert; M. Calderon; G. W. Canonica; S. R. Durham; H. J. Malling; U. Wahn; A. Sheikh

doi:https://doi.org/10.1111/all.13420

EAACI Guidelines on Allergen Immunotherapy: Executive Statement

A. Muraro, G. Roberts, S. Halken, A. Agache, L. Angier, M. Fernandez-Rivas, R. Gerth van Wijk, M. Jutel, S. Lau, G. Pajno, O. Pfaar, D. Ryan, G. J. Sturm, R. van Ree, E.-M. Varga, C. Bachert, M. Calderon, G. W. Canonica, S. R. Durham, H. J. MallingU. Wahn, A. Sheikh

Research output: Contribution to journal › Article › Academic › peer-review

126 Citations (Scopus)

Abstract

The allergist's community has recently celebrated 100 year of Allergen Immunotherapy (AIT). Unfortunately the implemention of this treatment is still impaired by some challenges. With the diversity of definitions, methodology and different allergen products used, research studies have produced conflicting outcomes. This has resulted in confusion about the benefits and risks of AIT amongst policymakers and professionals, as well as in the variable availability of AIT products, regulation and reimbursement policies globally. In 2015 EAACI initiated the AIT Guidelines project as part of the Presidential plan in order to settle the controversies. This article is protected by copyright. All rights reserved

Original language	English
Pages (from-to)	739-743
Journal	Allergy
Volume	73
Issue number	4
DOIs	https://doi.org/10.1111/all.13420
Publication status	Published - 2018

Access to Document

https://doi.org/10.1111/all.13420

Cite this

Muraro, A., Roberts, G., Halken, S., Agache, A., Angier, L., Fernandez-Rivas, M., Gerth van Wijk, R., Jutel, M., Lau, S., Pajno, G., Pfaar, O., Ryan, D., Sturm, G. J., van Ree, R., Varga, E.-M., Bachert, C., Calderon, M., Canonica, G. W., Durham, S. R., ... Sheikh, A. (2018). EAACI Guidelines on Allergen Immunotherapy: Executive Statement. Allergy, 73(4), 739-743. https://doi.org/10.1111/all.13420

@article{b0cb58080dcb408ea78f61147080d8df,

title = "EAACI Guidelines on Allergen Immunotherapy: Executive Statement",

abstract = "The allergist's community has recently celebrated 100 year of Allergen Immunotherapy (AIT). Unfortunately the implemention of this treatment is still impaired by some challenges. With the diversity of definitions, methodology and different allergen products used, research studies have produced conflicting outcomes. This has resulted in confusion about the benefits and risks of AIT amongst policymakers and professionals, as well as in the variable availability of AIT products, regulation and reimbursement policies globally. In 2015 EAACI initiated the AIT Guidelines project as part of the Presidential plan in order to settle the controversies. This article is protected by copyright. All rights reserved",

author = "A. Muraro and G. Roberts and S. Halken and A. Agache and L. Angier and M. Fernandez-Rivas and {Gerth van Wijk}, R. and M. Jutel and S. Lau and G. Pajno and O. Pfaar and D. Ryan and Sturm, {G. J.} and {van Ree}, R. and E.-M. Varga and C. Bachert and M. Calderon and Canonica, {G. W.} and Durham, {S. R.} and Malling, {H. J.} and U. Wahn and A. Sheikh",

year = "2018",

doi = "https://doi.org/10.1111/all.13420",

language = "English",

volume = "73",

pages = "739--743",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "4",

}

Muraro, A, Roberts, G, Halken, S, Agache, A, Angier, L, Fernandez-Rivas, M, Gerth van Wijk, R, Jutel, M, Lau, S, Pajno, G, Pfaar, O, Ryan, D, Sturm, GJ, van Ree, R, Varga, E-M, Bachert, C, Calderon, M, Canonica, GW, Durham, SR, Malling, HJ, Wahn, U & Sheikh, A 2018, 'EAACI Guidelines on Allergen Immunotherapy: Executive Statement', Allergy, vol. 73, no. 4, pp. 739-743. https://doi.org/10.1111/all.13420

TY - JOUR

T1 - EAACI Guidelines on Allergen Immunotherapy: Executive Statement

AU - Muraro, A.

AU - Roberts, G.

AU - Halken, S.

AU - Agache, A.

AU - Angier, L.

AU - Fernandez-Rivas, M.

AU - Gerth van Wijk, R.

AU - Jutel, M.

AU - Lau, S.

AU - Pajno, G.

AU - Pfaar, O.

AU - Ryan, D.

AU - Sturm, G. J.

AU - van Ree, R.

AU - Varga, E.-M.

AU - Bachert, C.

AU - Calderon, M.

AU - Canonica, G. W.

AU - Durham, S. R.

AU - Malling, H. J.

AU - Wahn, U.

AU - Sheikh, A.

PY - 2018

Y1 - 2018

N2 - The allergist's community has recently celebrated 100 year of Allergen Immunotherapy (AIT). Unfortunately the implemention of this treatment is still impaired by some challenges. With the diversity of definitions, methodology and different allergen products used, research studies have produced conflicting outcomes. This has resulted in confusion about the benefits and risks of AIT amongst policymakers and professionals, as well as in the variable availability of AIT products, regulation and reimbursement policies globally. In 2015 EAACI initiated the AIT Guidelines project as part of the Presidential plan in order to settle the controversies. This article is protected by copyright. All rights reserved

AB - The allergist's community has recently celebrated 100 year of Allergen Immunotherapy (AIT). Unfortunately the implemention of this treatment is still impaired by some challenges. With the diversity of definitions, methodology and different allergen products used, research studies have produced conflicting outcomes. This has resulted in confusion about the benefits and risks of AIT amongst policymakers and professionals, as well as in the variable availability of AIT products, regulation and reimbursement policies globally. In 2015 EAACI initiated the AIT Guidelines project as part of the Presidential plan in order to settle the controversies. This article is protected by copyright. All rights reserved

U2 - https://doi.org/10.1111/all.13420

DO - https://doi.org/10.1111/all.13420

M3 - Article

C2 - 29380390

SN - 0105-4538

VL - 73

SP - 739

EP - 743

JO - Allergy

JF - Allergy

IS - 4

ER -